Virtus Investment Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Virtus Investment Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Buy	73,507 +20,240	+38%	+$323K	0.29%	172
2026 Q1	$789K	Buy	53,267 +10,150	+24%	+$148K	0.22%	162
2025 Q4	$688K	Sell	43,117 -10,880	-20%	-$154K	0.19%	174
2025 Q3	$597K	Hold	53,997	–	–	0.17%	189
2025 Q2	$457K	Buy	53,997 +16,946	+46%	+$136K	0.15%	193
2025 Q1	$298K	Sell	37,051 -45,777	-55%	-$371K	0.08%	242
2024 Q4	$744K	Hold	82,828	–	–	0.58%	40
2024 Q3	$607K	Hold	82,828	–	–	0.48%	55
2024 Q2	$473K	Buy	+82,828	New	+$436K	0.4%	80

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's AUPH Position: Q2 2026 in Review

Virtus Investment Advisers increased its Aurinia Pharmaceuticals (AUPH) stake by 38% in Q2 2026, buying an estimated $323K and bringing the position to 73,507 shares worth $1.25M. The position accounts for 0.29% of the portfolio, ranked #172.

Virtus Investment Advisers first reported a position in AUPH in Q2 2024 and has held it in 9 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Virtus Investment Advisers held 73,507 shares of Aurinia Pharmaceuticals worth $1.25M as of Q2 2026.
Virtus Investment Advisers bought 20,240 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $323K.
Aurinia Pharmaceuticals made up 0.29% of Virtus Investment Advisers's portfolio in Q2 2026, its #172 holding.
Virtus Investment Advisers first reported a position in Aurinia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.